IDEAS home Printed from https://ideas.repec.org/a/ecr/col070/45974.html
   My bibliography  Save this article

A comparative analysis of medicine prices in Latin America

Author

Listed:
  • Alvarez E., Roberto
  • González, Aldo

Abstract

This paper compares medicine prices in the six largest economies in Latin America. Using a panel-based econometric model with country fixed effects and controlling for variables related to the medicines’ characteristics, the comparison covers 19,741 units sold during the 2010–2015 period and has been carried out at the wholesale and retail levels and by type of medication (innovative, branded generic and generic). At the aggregate level and at the retail pharmacy level, the classification from least to most expensive is: Peru, Mexico, Argentina, Chile, Colombia and Brazil. In innovative medicines, Argentina and Peru have the lowest prices. In branded generic medicines, Mexico and Argentina have the lowest prices, while for pure generics, Peru and Chile appear to be the least expensive. The classification does not change substantially if ex-factory prices are compared.

Suggested Citation

  • Alvarez E., Roberto & González, Aldo, 2020. "A comparative analysis of medicine prices in Latin America," Revista CEPAL, Naciones Unidas Comisión Económica para América Latina y el Caribe (CEPAL), April.
    • Handle: RePEc:ecr:col070:45974
    as

    Download full text from publisher

    File URL: http://repositorio.cepal.org/handle/11362/45974
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. -, 2020. "CEPAL Review no. 130," Revista CEPAL, Naciones Unidas Comisión Económica para América Latina y el Caribe (CEPAL), April.
    2. Patricia M. Danzon & Michael F. Furukawa, 2011. "Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets," NBER Working Papers 17226, National Bureau of Economic Research, Inc.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Eduardo Pontual Ribeiro & Victor Gomes, 2016. "Retail Entry Effects On Pharmaceuticals Prices: A View From Large Retail Chains In Brazil," Anais do XLIII Encontro Nacional de Economia [Proceedings of the 43rd Brazilian Economics Meeting] 139, ANPEC - Associação Nacional dos Centros de Pós-Graduação em Economia [Brazilian Association of Graduate Programs in Economics].
    2. Belmartino, Andrea & Calá, Carla Daniela, 2020. "A regional approach to the study of industrial diversity in Argentina (1996–2012)," Revista CEPAL, Naciones Unidas Comisión Económica para América Latina y el Caribe (CEPAL), April.
    3. Bence Kovács & Miklós Darida & Judit Simon, 2021. "Drugs Becoming Generics—The Impact of Genericization on the Market Performance of Antihypertensive Active Pharmaceutical Ingredients," IJERPH, MDPI, vol. 18(18), pages 1-20, September.
    4. Berrou, Jean-Philippe & Clément, Matthieu & Combarnous, François & Darbon, Dominique & Fauré, Yves-André, 2020. "Anatomy of the Brazilian middle class: identification, behaviours and expectations," Revista CEPAL, Naciones Unidas Comisión Económica para América Latina y el Caribe (CEPAL), April.
    5. George A. Chressanthis & Nayla G. Dahan & Kevin J. Fandl, 2015. "The Effects of State Pharmacy Drug Product Selection Laws on Statin Patient Generic-To-Branded Drug Switch-Backs," The American Economist, Sage Publications, vol. 60(1), pages 26-51, May.
    6. Vaca Medina, Gustavo & Vaca, Jesús & Mora Pérez, César Omar, 2020. "The impact of public debt on economic growth: an empirical study of Mexico (1994–2016)," Revista CEPAL, Naciones Unidas Comisión Económica para América Latina y el Caribe (CEPAL), April.
    7. Serra-Sastre, Victoria & Bianchi, Simona & Mestre-Ferrandiz, Jorge & O’Neill, Phill, 2021. "Does NICE influence the adoption and uptake of generics in the UK?," LSE Research Online Documents on Economics 113639, London School of Economics and Political Science, LSE Library.
    8. Berndt, Ernst R. & Dubois, Pierre, 2012. "Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010," IDEI Working Papers 702, Institut d'Économie Industrielle (IDEI), Toulouse.
    9. Sébastien CARRERE & Matthieu CLEMENT & François COMBARNOUS & Gabriel KESSLER & Eric ROUGIER & Ariel WILKIS, 2022. "The middle class in Argentina: dynamics, characteristics and implications for public policies," Working Paper 83de5468-cd86-4702-a4a8-6, Agence française de développement.
    10. Sotiris Vandoros, 2014. "Therapeutic Substitution Post‐Patent Expiry: The Cases Of Ace Inhibitors And Proton Pump Inhibitors," Health Economics, John Wiley & Sons, Ltd., vol. 23(5), pages 621-630, May.
    11. Roberto Álvarez & Aldo González, 2018. "Análisis Comparativo de Precios de Medicamentos en América Latina," Working Papers wp462, University of Chile, Department of Economics.
    12. Hokkanen, Joni & Kangasharju, Aki & Linnosmaa, Ismo & Valtonen, Hannu, 2012. "Generic substitution policy, prices and market structure: evidence from a quasi-experiment in Finland," Working Papers 35, VATT Institute for Economic Research.
    13. Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse, 2015. "Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement," Health Economics, John Wiley & Sons, Ltd., vol. 24(2), pages 238-252, February.
    14. Katharina Elisabeth Fischer & Tom Stargardt, 2016. "The diffusion of generics after patent expiry in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 1027-1040, November.
    15. Vitorio, Lúcia Nunes de Barros & Araújo, Jevuks Matheus de & Lima, Sergiany da Silva & Arruda, Danilo Raimundo de, 2020. "The importance of the BRICS group in the specialization of production and export competitiveness of North-East Brazil," Revista CEPAL, Naciones Unidas Comisión Económica para América Latina y el Caribe (CEPAL), April.
    16. Frank R. Lichtenberg, 2019. "How Many Life-Years Have New Drugs Saved? A 3-Way Fixed-Effects Analysis of 66 Diseases in 27 Countries, 2000-2013," NBER Working Papers 25483, National Bureau of Economic Research, Inc.
    17. Jaume Puig-Junoy, 2012. "Do Higher-Priced Generic Medicines Enjoy a Competitive Advantage Under Reference Pricing?," Applied Health Economics and Health Policy, Springer, vol. 10(6), pages 441-451, November.
    18. Eric Rougier & Jean‐Philippe Berrou & Matthieu Clément & François Combarnous & Dominique Darbon, 2021. "Should we call it a (middle) class? A socio‐economic exploration of the Vietnamese middle‐income group," Journal of International Development, John Wiley & Sons, Ltd., vol. 33(8), pages 1321-1345, November.
    19. Díaz Rodríguez, Héctor Eduardo & Aroche Reyes, Fidel, 2020. "Determinants of labour productivity in Mexico: an approach from the endogenous growth theory using artificial neural networks," Revista CEPAL, Naciones Unidas Comisión Económica para América Latina y el Caribe (CEPAL), April.
    20. Farasat A.S. Bokhari & Weijie Yan, 2020. "Product line extensions under the threat of entry: evidence from the UK pharmaceuticals market," Working Paper series, University of East Anglia, Centre for Competition Policy (CCP) 2020-04, Centre for Competition Policy, University of East Anglia, Norwich, UK..

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ecr:col070:45974. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Biblioteca CEPAL (email available below). General contact details of provider: https://edirc.repec.org/data/eclaccl.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.